Document Type: Research article
Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Faculty of Pharmacy, ShahidBeheshti University of Medical Sciences, Tehran, Iran
Pediatric Congenital Hematologic Disorders Research Center, ShahidBeheshti University of Medical Sciences, Tehran, Iran
B-acute lymphoblastic leukemia (B-ALL) is the frequent pediatric malignity. Chemotherapy is the most practical approaches to deal with such malignancies. Microtubule-targeted agents are one of the most strategic drugs which formerly use in chemotherapy.Although,colchicine-binding anti-tubulin agents exhibited promising effects in clinical trials, their exact mechanism of action is not fully understood.In this study, the effects of two newly synthesized of colchicine derivatives were investigated on cell viability of cancerous and normal lymphocytes. The viability test was carried out by MTT assay. Apoptosis vs. necrosis was measured by double staining with annexin V/PI, and caspase-3 as the ultimate mediator of apoptotic measured through the colorimetric assay. Parameters of mitochondrial damage (ROS formation, MMP decline, mitochondrial swelling, and cytochrome c release following treatment by colchicine derivatives.
By focusing on mitochondrial parameters, we showed that following treatment by two newly synthetized colchicine derivatives, apoptosis are triggered in cancerous B-lymphocytes. We demonstrated these compounds could activate apoptosis in cancerous lymphocytes by augmentation of reactive oxygen species (ROS), a decline in mitochondrial membrane potential (MMP), mitochondrial swelling, release of cytochrome c and also caspase-3 activation.
Considering the obtained evidences, these inhibitorscould be the new therapeutic strategies in ALL treatment.